News
Product launch: Pig NGAL ELISA Kit (KIT 044)
August 16 2010
BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
August 12 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010
IUTOX 2010, July 19-23, Barcelona, Spain
June 30 2010
BioPorto Diagnostics at the ERA-EDTA Congress, Munich, June 25-28
June 14 2010
BioPorto Diagnostics at APCN 2010, June 5-8, Seoul, Korea
May 21 2010
Presentation of The NGAL Test data at the BRS/RA Conference, May 17-20, Manchester, UK
May 14 2010
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
TSIS 2010, March 9-13, Munich, Germany
February 18 2010
ToxExpo, March 7-11, Salt Lake City, Utah
February 16 2010
MEDICA, November 18-21, Düsseldorf, Germany
November 09 2009 by Ana Belén Enfedaque Buisán
As the world’s largest medical trade fair, this year’s MEDICA once again offers a comprehensive overview of a wide variety of innovations in the world of healthcare. This leading medical fair gives decision makers from around the world the opportunity to find out about the latest developments in their field and to discuss their field of specialization.
BioPorto Diagnostics will participate in MEDICA showcasing The NGAL Test as well as the latest developments in its portfolio.
Meet us at stand K88, Hall 3:
Trine Østerbye, Sales and Marketing Manager toe@bioporto.com
Ishan Gupta, Business Development Manager Sales ig@bioporto.com
Jakob Ohm Eriksen, Pharma Diagnostics Product Manager joe@bioporto.com
Klaus Boberg Pedersen, Human Diagnostics Product Manager kbp@bioporto.com
Ana Belén Enfedaque, Marketing Coordinator aeb@bioporto.com
For further information on MEDICA, please click here
DISTRIBUTOR MEETING 2009
Following the highly successful 2008 meeting, MEDICA, the hub of the medical trade, will once again become the meeting point for our distributors this year. In a plenary session which will be held on Tuesday, November, 17, we will not only share knowledge for the development of our present business partnerships but also discuss both product and market potential in the different territories in which our products are commercialized.
